Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Alasdair J ColesAnat AchironAnthony TraboulseeBarry A SingerCarlo PozzilliCelia Oreja-GuevaraGavin GiovannoniGiancarlo ComiMark S FreedmanTjalf ZiemssenDebora ShiotaAndreea M RawlingsAlana T WongMagdalena ChirieacXavier MontalbanPublished in: Therapeutic advances in neurological disorders (2023)
NCT00530348; NCT00548405; NCT00930553; NCT02255656.